Jazz launches Sunosi

Jazz Pharmaceuticals has launched its new sleep drug Sunosi (solriamfetol) which received FDA approval for narcolepsy and obstructive sleep apnea (OSA). There is an advertising campaign aimed at neurologists, psychiatrists, pulmonologists and sleep specialists which will be delivered by a bolstered salesforce.
Jazz CEO Bruce Cozadd said: “…in the case of narcolepsy patients, I think it’s what treatment are they going to use, and in the case of OSA patients, for many of them it will be getting treatment at all….In today’s society, sleepiness is almost worn as a badge of honour. ‘I work so hard and I don’t get enough sleep,’ that’s viewed as OK. Obviously for these patients and this disease it’s not at all OK, and helping to educate them that what they’re viewing as normal is not normal we think will lead more patients to get better treatment and have a better life.”